Printer Friendly

More options for HIV.

A combination of atovaquone-azithromycin (AT-AZ) is as effective as trimethoprim-sulfamethoxazole (TMP-SMZ) for the prevention of serious bacterial infections in children with HIV aged 3 months to 19 years, said Walter T. Hughes, M.D., of St. Jude Children's Research Hospital, Memphis, and his colleagues.

TMP-SMZ is widely used against bacterial infections in children with and without HIV, but some children experience adverse reactions and need an alternative treatment.

In a randomized, double-blind, placebo-controlled study, 366 children were followed for an average of 3 years (Clin. Infect. Dis. 2005;40:136-45). Serious bacterial infections were 12.9/100 personyears in the AT-AZ group, compared with 18.5/100 person-years in the TMP-SMZ group.

Hematologic problems were the most common adverse events, occurring in 39% of the AT-AZ children and 37% of the TMP-SMZ children. While the high cost of atovaquone-azithromycin prevents its use in most cases, it presents a viable alternative for children who experience adverse effects from TMP-SMZ, researchers said.

COPYRIGHT 2005 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:prevention of infectious diseases in children
Publication:Family Practice News
Article Type:Brief Article
Geographic Code:1USA
Date:Jul 15, 2005
Previous Article:Tularemia from hamster bite.
Next Article:Teens and tobacco addiction.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters